TX Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Not a good buy right now for an impatient investor. TX is sitting just above near-term support after a sharp -3.95% regular-session drop, momentum is weakening (MACD histogram negative and expanding), and the only listed Street view is Neutral with a $39 target (below the current ~$41.8). I would avoid initiating a new long here; it’s a HOLD/WAIT rather than a buy.
Price/levels: Post-market ~$41.8, trading below the pivot (42.732) and just above S1 (41.57); a clean breakdown risks a move toward S2 (40.853). Upside needs a reclaim of the pivot, then R1 (43.893). Trend: Moving averages are structurally bullish (SMA_5 > SMA_20 > SMA_200), but short-term momentum is deteriorating. Momentum: MACD histogram -0.0574 (below 0 and negatively expanding) signals bearish acceleration. RSI_6 ~40.14 is weak/neutral (not deeply oversold), suggesting downside pressure can persist. Pattern-based odds: Similar-pattern stats imply modest positive drift over 1W/1M (about +1.52% / +2.33%), but near-term (next day) is roughly flat to slightly negative.
Intellectia Proprietary Trading Signals
on 2026-02-17 after hours could act as a catalyst if results/guide confirm the much higher EPS expectation (Est. 1.48). Gross margin improved YoY in 2025/Q3 (15.38%, +19.13% YoY), suggesting some cost/price discipline despite the downturn. Options volume skew is call-heavy today (bullish lean).
were weak: revenue -11.74% YoY, net income -34.90% YoY, EPS -50% YoY—pressure likely tied to steel/industrial cycle softness. No supportive hedge fund/insider buying trends were flagged.
Latest quarter: 2025/Q3. Revenue was 3.954B (-11.74% YoY), net income 20.6M (-34.90% YoY), EPS 0.01 (-50.00% YoY). The bright spot was profitability mix: gross margin rose to 15.38% (+19.13% YoY). Overall: top-line and earnings contracted meaningfully, while margins improved—still a net negative growth picture into the next earnings event (QDEC 2025 on 2026-02-17).
Most recent item: 2025-12-15 UBS maintained a Neutral rating and raised the price target to $39 from $32. Directionally, that’s an improved target, but it still sits below the current ~$41.8, signaling Wall Street’s pros/cons are balanced-to-cautious: modestly better outlook than before, but not enough to recommend buying at current levels.
